Preclinical studies have indicated that these therapies may also be effective against breast cancers with low HER2 expression, which is defined as a HER2 immunohistochemistry (IHC) score of 1 or 2 with a negative in situ hybridization (ISH) assay [18,19,20]. Here, ERBB2 is linked to breast carcinoma.